



ADVITECH ANNOUNCES NEW EFFICACY RESULTS FOR DERMYLEX™ AND COMPLIANCE WITH FDA REGULATIONS ON CLAIMS

FOR IMMEDIATE RELEASE

TSX VENTURE EXCHANGE: AVI

DERMYLEX™ AND PSORIASIS

QUEBEC CITY, QUEBEC — September 12, 2007 — Advitech Inc. (“Advitech” or the “Corporation”) (TSX Venture Exchange: AVI) announced today that a post-marketing study conducted on patients suffering from psoriasis shows that the use of Dermylex™ may benefit patients already using topical corticosteroids. Using Dermylex™ with topical corticosteroids may create a synergistic effect and improve overall treatment efficacy results. Therefore, Dermylex™ might act as an adjuvant to topical corticosteroids.

“This new data provides Advitech and its commercial partners with important information on treatment strategies and alternatives. Adding Dermylex™ to a topical corticosteroid treatment appears to reduce psoriasis severity,” stated Dr. Christina Juneau, Advitech’s Vice-President of Research and Development. “Advitech will continue to gather and monitor additional data and results from this post-marketing study in order to develop therapeutic strategies for Dermylex™ users.”

These observations arise from a study by Advitech in which Dermylex™ users were invited to provide their own evaluation and comment on the results obtained with Dermylex™ whether taken alone or part of a concomitant treatment for psoriasis. In the questionnaire, psoriasis severity was quantified by means of an intensity scale.

ADVITECH RECEIVES CONFIRMATION FROM FDA THAT DERMYLEX™ CLAIMS MEET U.S REGULATIONS

Advitech had submitted to the U.S. Food and Drug Administration (FDA), in June of this year, four different structure/function claims in relation to Dermylex™ and recently received confirmation by FDA’s Division of Dietary Supplement Programs that all four claims are acceptable under the agency’s regulations. These claims will be used for labeling purpose in the commercialization of Dermylex™ by Advitech’s partner in the U.S market.

“Regulations applicable to the U.S market are strict as they relate to the labeling of products like Dermylex™. This confirmation from the FDA is important for Advitech and its marketing partners as it will help position Dermylex™ in this strategic market,” added Dr. Juneau.

About Advitech Inc. www.advitech.com

Advitech is a health sciences and technology company with a mission to discover and commercialize proprietary and evidence-based natural health products. Effective and safe, these products play a role in the prevention of Immune-mediated inflammatory disorders, such as psoriasis and inflammatory bowel disease.

About Dermylex™ www.dermylex.com

Dermylex™, developed by Advitech, is an oral natural health product formulated to improve mild-to-moderate psoriasis symptoms. Two clinical trials, one of them a multi-center, double-blind, placebo-controlled trial with 84 patients for 112 days, clinically proved the efficacy and safety of

Dermylex™ for that type of psoriasis. Dermylex™ is currently available in Canada and will soon be available in the U.S. (as BioDerm), and in France and Belgium (as Psopax).

-30-

This press release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

For further information, please contact:

Advitech Inc.

Renaud Beauchesne, MBA
President and Chief Executive Officer
418-686-7498, ext. 228
info@advitech.com
www.advitech.com

Serge Comeau
Investor's relations
514-862-4160
s.comeau@advitech.com